source
- Novo Nordisk halts two cardiovascular trials of inflammation-targeting drug ziltivekimabNovo Nordisk announced it is halting the HERMES and ATHENA cardiovascular trials of its experimental drug ziltivekimab, which was intended to lower inflammation to improve heart health. A data mon…
- Novartis' experimental heart drug pelacarsen fails pivotal Phase 3 trialNovartis announced that its experimental cardiovascular therapy, pelacarsen, did not meet its primary endpoints in the Phase 3 HORIZON trial. The study compared the drug to placebo and found no red…